ReviewThe oncologist2008
Carcinoid tumors.
Review in The oncologist, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 229 citations in OpenAlex.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.Cancer chemotherapy and pharmacology · 2013Trial
- A preclinical and clinical study of lithium in low-grade neuroendocrine tumors.The oncologist · 2011Trial
- A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma.The oncologist · 2011Trial
- Multimodality Diagnosis and Management of Carcinoid Heart Disease: Outcomes and Long-Term Follow-Up.JACC. Case reports · 2026Article
- World's Largest Single-Surgeon Experience in Robotic Resection of Pulmonary and Bronchial Carcinoid Tumors.Journal of robotic surgery · 2026Article
- The rare case of carcinoid tumor in mid ileal segment causing intestinal obstruction.Journal of family medicine and primary care · 2026Article
- From diagnosis to treatment: navigating the course for pancreatic neuroendocrine neoplasms.Annals of medicine · 2025Review
- Expanding the therapeutic horizon ofNagoya journal of medical science · 2025Review
- Article
- Article
- Contralateral metachronous pulmonary carcinoid tumor 7 years after lobectomy.Indian journal of thoracic and cardiovascular surgery · 2025Article
- Vertebral Metastasis in a Bronchial Carcinoid: A Rare Case Report with More than 3-Year Follow-Up and Review of the Literature.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- A case of appendiceal neuroendocrine tumor with metastatic spread in a young patient.SAGE open medical case reports · 2025Article
- A Rare Discovery of Neuroendocrine Tumor: Cardiac Mass.Journal of community hospital internal medicine perspectives · 2025Article
- Carcinoid Tumor of the Duodenum Presenting as Iron Deficiency Anemia.Oman medical journal · 2025Article
- A Challenging Decision: Identifying and Managing Hepatic Hydrothorax in the Setting of a Pancreatic Neuroendocrine Tumor.Case reports in gastrointestinal medicine · 2025Article
- Atypical Cerebral Carcinoids Treated with Hippocampal-Sparing Whole Brain Radiotherapy.Cureus · 2024Article
- Synchronous bilateral typical pulmonary carcinoid tumours diagnosed by robotic navigation bronchoscopy: A unique case.Respirology case reports · 2024Article
- Current perspectives on neuroendocrine tumors.hLife · 2024Review
55 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Carcinoid tumors are rare, slow-growing neuroendocrine tumors arising from the enterochromaffin cells disseminated throughout the gastrointestinal and bronchopulmonary systems. Though they have been traditionally classified based on embryologic site of origin, morphologic pattern, and silver affinity, newer classification systems have been developed to emphasize the considerable clinical and histopathologic variability of carcinoid tumors found within each embryologic site of origin. These neoplasms pose a diagnostic challenge because they are often innocuous at the time of presentation, emphasizing the need for a multidisciplinary diagnostic approach using biochemical analysis, standard cross-sectional imaging, and newer advances in nuclear medicine. Similarly, treatment of both primary and disseminated carcinoid disease reflects the need for a multidisciplinary approach, with surgery remaining the only curative modality. The prognosis for patients with these tumors is generally favorable; however, it can be quite variable and is related to the location of the primary tumor, extent of metastatic disease at initial presentation, and time of diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.